BagheraniNSmollerBR. An overview of cutaneous T cell lymphomas. F1000Res. 2016;5:F1000 Faculty Rev-1882. doi:10.12688/f1000research.8829.1
2.
García-DíazNPirisMÁOrtiz-RomeroPLVaquéJP. (2021). Mycosis fungoides and Sézary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers. 2021;13(8):1931. doi:10.3390/cancers13081931
3.
PelcovitsAOllilaTAOlszewskiAJ. Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma. Cancer Manage Res. 2023;15:989-998. doi:10.2147/CMAR.S330908
4.
SauliteIIgnatovaDChangYT, et al. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology. 2020;9(1):1738797. doi:10.1080/2162402X.2020.1738797
5.
KhodadoustMSRookAHPorcuP, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20-28. doi:10.1200/JCO.19.01056
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
